New Delhi: In a major step toward tackling the global HIV epidemic, Indian pharmaceutical companies Dr. Reddy’s Laboratories and Hetero Labs have announced plans to introduce affordable generic versions of a groundbreaking HIV prevention drug by 2027. The drug will be available for $40 per year, or Rs 3548 in INR.

Where was lenacapavir developed?

The drug, lenacapavir, was developed by U.S.-based Gilead Sciences and is marketed under the brand name Yeztugo. Approved earlier this year, the drug is administered as an injection just twice a year and demonstrated nearly 100% effectiveness in large-scale clinical trials. Experts say it has the potential to reshape the fight against HIV, a disease that continues to infect 1.3 million people annually and has claimed more than 44 million lives o

See Full Page